Zepbound for Sleep Apnea (OSA): The Patient Action Plan

In December 2024 the FDA approved Zepbound (tirzepatide) as the first prescription medication ever indicated for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The approval was based on SURMOUNT-OSA (Malhotra et al., NEJM 2024^[1]), a Phase 3 trial that cut the apnea-hypopnea index (AHI) by roughly half — about 25–29 fewer breathing events per hour, from a baseline near 50. This is a patient-facing action plan: how OSA is diagnosed today, who qualifies for Zepbound, when CPAP is still required, what to expect from insurance, and why Wegovy is not FDA-approved for OSA even though it sounds like it should be. Every numerical claim below is anchored to the primary trial publication, the FDA approval letter, the AASM 2017 diagnostic guideline^[8], or the published OSA epidemiology^[6].

The honest summary

• OSA is defined by the apnea-hypopnea index (AHI): AHI 5–14.9 with daytime symptoms (sleepiness, fatigue, mood disturbance) or AHI ≥ 15 regardless of symptoms is the AASM threshold. Moderate OSA is AHI 15–29.9; severe is AHI ≥ 30^[8].
• OSA is common in obesity. The Wisconsin Sleep Cohort update (Peppard 2013^[7]) estimated AHI ≥ 15 in roughly 13% of US men and 6% of US women aged 30–70, with prevalence climbing sharply with BMI. In adults with class II–III obesity, moderate-to-severe OSA prevalence exceeds 25–40% in most surgical and obesity-medicine populations. Global estimate: ~936 million adults aged 30–69 have at least mild OSA (Benjafield 2019^[6]).
• Zepbound (tirzepatide) is FDA-approved for OSA since December 2024 in adults with moderate-to-severe OSA and obesity (BMI ≥ 30), as an adjunct to a reduced- calorie diet and increased physical activity^[2]. The approval came from SURMOUNT-OSA^[1], which ran two parallel trials: one in adults not on positive airway pressure (Study 1) and one in adults on positive airway pressure at baseline (Study 2).
• Magnitude. Across both SURMOUNT-OSA studies the AHI fell by roughly 25–29 events/hour on tirzepatide versus ~5–6 events/hour on placebo, from a mean baseline of ~50 events/hour^[1]. About half of tirzepatide- treated participants reached the disease-resolution threshold (AHI < 5 with no daytime symptoms, or AHI < 10 alone, depending on definition).
• Wegovy (semaglutide 2.4 mg) is NOT FDA-approved for OSA. Semaglutide does not have a completed positive Phase 3 OSA trial. STEP-1^[4] and the cardiovascular SELECT trial enrolled adults with obesity but did not measure AHI as a primary endpoint. The tirzepatide indication does not generalize to semaglutide, and a clinician cannot prescribe Wegovy “for OSA” and expect insurance to cover it.
• CPAP is still the standard. Tirzepatide does not replace CPAP at diagnosis for most patients. Current AASM clinical practice still treats positive airway pressure as first-line for moderate-to-severe OSA. Zepbound is an adjunct — or, in selected patients who lose enough weight, a path toward eventual CPAP de-escalation under sleep-medicine supervision.
• You still need a sleep study. The FDA indication requires a documented OSA diagnosis. A home sleep apnea test (HSAT) or in-lab polysomnography (PSG) is the gateway. Insurance will not approve Zepbound “for OSA” on suspicion alone^[8].

What obstructive sleep apnea actually is

Obstructive sleep apnea is repeated collapse of the upper airway during sleep. Each collapse stops or reduces airflow for at least 10 seconds, drops blood oxygen, and triggers a brief micro-arousal as the brain partially wakes the body to re-open the airway. The patient typically does not remember these arousals — the spouse or bed partner hears the gasping, choking, and snoring. Daytime consequences are what bring most patients to clinic: unrefreshing sleep, morning headaches, excessive daytime sleepiness, mood disturbance, and impaired concentration.

The clinical metric is the apnea-hypopnea index (AHI) — the average number of apneas (complete airflow stoppages) plus hypopneas (partial reductions in airflow with oxygen desaturation or arousal) per hour of sleep. The AASM^[8] defines severity as:

• Mild: AHI 5–14.9 (clinical OSA requires associated symptoms or comorbidities at this threshold)
• Moderate: AHI 15–29.9
• Severe: AHI ≥ 30

Untreated moderate-to-severe OSA is associated with cardiovascular consequences: hypertension, atrial fibrillation, stroke, heart failure (particularly HFpEF), and increased all-cause mortality in observational cohorts. It is also a leading reversible cause of treatment-resistant hypertension. The cardiometabolic story is part of why SURMOUNT-OSA matters — tirzepatide reduced not just AHI but blood pressure, hsCRP, and body weight in the same trial population^[1].

SURMOUNT-OSA: the trial that earned the FDA approval

SURMOUNT-OSA^[1] was published in the New England Journal of Medicine in October 2024. The FDA approved Zepbound for moderate-to-severe OSA in obesity on December 20, 2024^[2]. The trial enrolled 469 adults with moderate-to-severe OSA (AHI ≥ 15) and obesity (BMI ≥ 30), split into two parallel 52-week randomized double-blind placebo-controlled studies:

• Study 1: participants not using positive airway pressure (PAP) at baseline (n=234)
• Study 2: participants using PAP at baseline (n=235), continued on PAP throughout the trial

In both studies, participants were randomized 1:1 to maximum tolerated tirzepatide (10 mg or 15 mg weekly) or matching placebo. Primary endpoint: change in AHI from baseline to week 52, measured by overnight in-lab polysomnography.

Headline result. Mean baseline AHI was about 51 (Study 1) and 49 (Study 2). At week 52:

• Study 1 (no PAP): tirzepatide reduced AHI by ~25 events/hour versus ~5 events/hour on placebo — a placebo-adjusted reduction of ~20 events/hour. About half of tirzepatide-treated participants reached the disease-resolution threshold.
• Study 2 (on PAP): tirzepatide reduced AHI by ~29 events/hour versus ~6 events/hour on placebo — placebo-adjusted reduction of ~23 events/hour.
• Body weight: tirzepatide produced ~18–20% mean weight loss across both studies, consistent with the SURMOUNT-1 obesity result of -20.9% at 72 weeks^[3].
• Secondary outcomes: patient-reported sleep impairment scores, hypoxemic burden, systolic blood pressure, and hsCRP all improved on tirzepatide versus placebo.

Sleep architecture. SURMOUNT-OSA also measured downstream sleep-quality variables. Hypoxemic burden (the time-weighted area under the oxygen desaturation curve) fell meaningfully on tirzepatide. The patient-reported sleep impairment score (PROMIS Sleep-Related Impairment) improved more on tirzepatide than placebo. The magnitude of architectural change tracked the magnitude of weight loss, consistent with the mechanism: less upper- airway fat and lower peri-pharyngeal soft-tissue volume.

Wegovy and semaglutide: why no OSA indication

A common patient question: “If Wegovy and Zepbound both cause weight loss, why is only Zepbound approved for OSA?” The answer is regulatory, not pharmacological. FDA indications are granted for specific drug-disease pairs based on adequate and well-controlled trials. The tirzepatide indication came from SURMOUNT-OSA^[1]. Semaglutide does not have an equivalent completed positive Phase 3 OSA trial. STEP-1^[4] measured body weight, not AHI. STEP-HFpEF^[5] measured heart failure symptoms and exercise tolerance, not AHI. SELECT measured cardiovascular events, not AHI.

Until Novo Nordisk runs (and publishes a positive) randomized OSA trial of semaglutide, the FDA cannot grant Wegovy an OSA indication, and insurers will not authorize Wegovy “for OSA.” A semaglutide patient with OSA can still benefit from weight loss, and the weight loss can still reduce AHI — the published magnitude of semaglutide weight loss in STEP-1 (~14.9% at 68 weeks^[4]) is meaningful — but the prescription and the prior authorization both still hang on the obesity indication, not OSA.

CPAP vs GLP-1 vs both: where each fits

The first practical question after a positive sleep study is which treatment goes first. The answer depends on severity, body habitus, comorbidities, and patient preference. The published evidence and current AASM practice support the following framework:

• Severe OSA (AHI ≥ 30) with significant comorbidities: CPAP is still first-line. Add Zepbound as adjunct in patients with BMI ≥ 30 who also meet obesity-medicine criteria. Goal: long-term sleep architecture restoration AND weight loss-driven anatomic improvement. Some patients eventually de-escalate to lower PAP pressures or to oral appliances as AHI drops.
• Moderate OSA (AHI 15–29.9) with obesity (BMI ≥ 30): the population SURMOUNT-OSA enrolled. Zepbound monotherapy is now an evidence-based option per the FDA label. Many sleep-medicine clinicians still start CPAP and add Zepbound, especially when daytime sleepiness is severe and the patient needs immediate symptom control. CPAP works on night one; tirzepatide takes weeks to escalate and months to produce its full anatomic effect.
• CPAP-intolerant patients: the population most likely to benefit from a GLP-1-first strategy. Long-term CPAP adherence is poor — Sawyer 2011^[9] systematically reviewed adherence and found roughly 30–50% of patients are non-adherent at one year, depending on the definition (most commonly defined as <4 hours/night for ≥70% of nights). For these patients, Zepbound is a meaningful alternative or bridge, and SURMOUNT-OSA Study 1 specifically enrolled adults not on PAP^[1].
• Patients already on stable PAP: SURMOUNT-OSA Study 2 showed tirzepatide produces an additional ~23 events/hour AHI reduction on top of PAP^[1]. For these patients, the discussion is less “CPAP or Zepbound” and more “CPAP plus Zepbound, with the long-term goal of CPAP de-escalation if weight loss is sufficient.”
• Mild OSA (AHI 5–14.9): Zepbound is not FDA-approved at this severity for OSA. The obesity indication still applies if BMI criteria are met, and weight loss may improve mild OSA, but the OSA-specific authorization pathway only covers moderate-to-severe.

Critically, do not stop CPAP without sleep-medicine supervision. The temptation to abandon the mask as weight comes down is real, but residual OSA — even moderate — carries cardiovascular risk that the patient cannot feel. A repeat sleep study after meaningful weight loss (typically 6–12 months on Zepbound, ~15–20% weight loss) is the only way to know whether the OSA has resolved enough to justify de-escalation.

The cardiometabolic context: STEP-HFpEF and the broader story

SURMOUNT-OSA does not exist in isolation. The cardiometabolic story for GLP-1s in adults with obesity has been building for five years. Three trials matter for the OSA conversation:

STEP-HFpEF (Kosiborod 2023 NEJM^[5]) randomized 529 adults with HFpEF and obesity (BMI ≥ 30) to semaglutide 2.4 mg weekly or placebo for 52 weeks. Primary endpoint: change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score and percent change in body weight. Semaglutide produced significantly greater improvement in heart-failure symptoms, exercise tolerance (6-minute walk distance), and weight loss versus placebo. STEP-HFpEF is the trial that established obesity-associated HFpEF as a GLP-1-responsive condition. STEP-HFpEF did not measure AHI and is not an OSA trial — but a substantial fraction of HFpEF patients with obesity also have OSA, and the cardiometabolic improvement from weight loss is part of the integrated story that motivates trying GLP-1s in OSA.

SURMOUNT-1 (Jastreboff 2022 NEJM^[3]) established the body-weight magnitude for tirzepatide: -20.9% at 72 weeks for the 15 mg arm. SURMOUNT-OSA confirms that anatomic weight loss of that magnitude translates into airway-anatomy change measurable by overnight polysomnography.

SELECT (semaglutide cardiovascular outcomes, published 2023, cited elsewhere on this site) added the major adverse cardiovascular event reduction story to the semaglutide profile. SELECT did not measure AHI either.

How obstructive sleep apnea actually gets diagnosed

A Zepbound “for OSA” prescription requires a documented diagnosis. The 2017 AASM Clinical Practice Guideline for Diagnostic Testing for Adult OSA (Kapur et al.^[8]) is the framework most US sleep-medicine practices follow:

• Step 1: clinical evaluation. History, STOP-Bang or Epworth Sleepiness Scale screening, exam. High pre-test probability in obesity, hypertension, witnessed apneas, daytime sleepiness, neck circumference >17 inches (men) or >15 inches (women).
• Step 2: home sleep apnea test (HSAT) OR in-lab polysomnography (PSG). AASM^[8] recommends HSAT for uncomplicated adults with high pre-test probability of moderate-to-severe OSA. Patients with significant cardiopulmonary disease, neuromuscular weakness, history of stroke, severe insomnia, suspected central sleep apnea, or chronic opioid use should go directly to in-lab PSG.
• HSAT pros: faster, cheaper, at home in your own bed, often covered by insurance with minimal authorization. Limitations: measures airflow, oxygenation, and (with some devices) effort — not EEG sleep staging. A negative HSAT in a high-pre-test-probability patient should be followed by in-lab PSG.
• In-lab PSG pros: gold standard, full sleep architecture, EEG, EMG, EOG, pulse oximetry, airflow, effort, ECG. Diagnoses central sleep apnea, REM-related OSA, and complex/mixed apneas the HSAT cannot. Slower to schedule (often weeks); requires overnight stay in a sleep lab.
• Result: AHI value plus oxygen desaturation index plus arousal index, all reported on the sleep study summary. The number that drives the FDA Zepbound indication is AHI ≥ 15 with BMI ≥ 30.

Insurance, prior authorization, and Medicare DME interaction

The insurance side of the Zepbound-for-OSA conversation is not simple. The drug is the same compound as Zepbound-for- obesity, but the authorization pathway is different and the downstream interaction with durable medical equipment (DME) coverage (the CPAP machine) creates ongoing decisions.

• Commercial insurance prior authorization typically requires: documented OSA diagnosis (sleep study report attached), AHI ≥ 15, BMI ≥ 30, and prior or concurrent counseling on diet and exercise. Many plans also require documentation of CPAP intolerance or inadequate response — an important detail to discuss with the sleep-medicine prescriber.
• Medicare traditionally has not covered obesity drugs in Part D. The OSA indication is a separate authorization pathway. As of 2026 the Medicare Part D GLP-1 coverage landscape is in active flux (see our Medicare/Medicaid coverage explainer); patients should verify with their plan whether the OSA indication is recognized separately from obesity.
• DME coverage of CPAP requires ongoing documentation of use (typically ≥4 hours/night for ≥70% of nights over a 30-day window in the first 90 days). If a patient on Zepbound loses enough weight to come off CPAP, the DME contract may end — but the decision should be driven by a repeat sleep study, not by insurance economics.
• Switching from CPAP to Zepbound monotherapy is a sleep-medicine decision, not a patient decision. A repeat in-lab PSG or HSAT after meaningful weight loss is the only way to verify OSA resolution. Anecdotal symptom improvement (less daytime sleepiness, better mood) is encouraging but not sufficient.

How Zepbound for OSA compares with other interventions

Two things to keep in perspective. First, CPAP when fully adherent is still the most aggressive single-night AHI reducer — it can normalize AHI from night one. The Zepbound advantage is durability across the entire night regardless of mask tolerance, and the parallel weight loss and cardiometabolic benefit. Second, the magnitudes shown above are not all from the same trial; CPAP and oral appliance values are typical clinical-practice estimates drawn from the broader AASM literature, not direct comparisons inside SURMOUNT-OSA^[1].

Patient action plan

If you suspect you have OSA, or you have a known OSA diagnosis and want to know whether Zepbound is an option, the practical sequence is:

1. Confirm or get an OSA diagnosis. Ask your primary care clinician for a sleep-medicine referral, or go directly to a sleep-medicine practice that accepts self-referrals. Expect an HSAT or in-lab PSG as the next step. The AHI on that report is the gate.
2. Verify your BMI is ≥ 30. The Zepbound- for-OSA indication requires moderate-to-severe OSA AND obesity. If your BMI is < 30 but you have moderate-to- severe OSA, talk to sleep medicine about CPAP and oral appliance options first — the FDA OSA indication does not currently cover you.
3. Book a joint discussion with sleep medicine AND obesity medicine. Zepbound-for-OSA sits at the boundary between two specialties. The prescriber will most often be obesity medicine, primary care, or endocrinology; the diagnostic and follow-up sleep study falls under sleep medicine. Coordinating both up front prevents the “who owns this prescription” friction many patients hit later.
4. Bring the sleep study report to the authorization request. Insurance will require it. Have the AHI value, baseline BMI, and obesity-medicine documentation ready as a packet.
5. Do not stop CPAP without permission. Even after meaningful weight loss, CPAP de-escalation requires a repeat sleep study under sleep-medicine supervision. Stopping CPAP unilaterally because you feel better is not safe.
6. Expect 6–12 months before any CPAP-weaning conversation. SURMOUNT-OSA measured AHI at 52 weeks. The anatomic remodeling of the upper airway tracks the weight-loss curve, which takes months. A 4-week or 12-week check-in is for tolerability and titration, not for declaring victory.
7. Continue the lifestyle adjuncts. Side sleeping, alcohol reduction (alcohol worsens OSA), treatment of nasal obstruction, and weight loss-supportive exercise patterns all stack with both CPAP and Zepbound.

What the evidence does and does not say

What SURMOUNT-OSA does say:

• In adults with moderate-to-severe OSA and obesity, tirzepatide reduces AHI by ~25–29 events/hour over 52 weeks, with or without concurrent PAP^[1].
• The reduction is accompanied by ~18–20% body weight loss, improvements in patient-reported sleep impairment, systolic blood pressure, and hsCRP^[1].
• About half of treated participants reach AHI thresholds consistent with disease resolution definitions used in the trial^[1].
• The result was sufficient for the FDA to approve Zepbound for moderate-to-severe OSA in obesity in December 2024^[2] — the first prescription medication ever indicated for OSA.

What SURMOUNT-OSA does NOT say:

• Tirzepatide does not eliminate the need for CPAP in most patients at study entry. CPAP-adherent patients should not stop CPAP based on the trial without sleep-medicine re-evaluation.
• The trial does not address mild OSA (AHI 5–14.9), non-obese OSA (BMI < 30), pediatric OSA, central sleep apnea, or complex/mixed apneas.
• The trial result does not generalize to semaglutide, liraglutide, dulaglutide, or orforglipron. None of those drugs has a completed positive Phase 3 OSA trial. Wegovy is not FDA-approved for OSA.
• The 52-week result does not establish lifetime durability. Continuation of weight loss requires continuation of the drug; AHI reductions are presumed to revert if weight regain occurs after discontinuation.

Bottom line

• Zepbound is the first FDA-approved prescription medication for moderate-to-severe OSA in adults with obesity, approved December 2024^[2] based on SURMOUNT-OSA^[1].
• The trial showed ~25–29 events/hour AHI reduction over 52 weeks, both with and without concurrent PAP, on a baseline of ~50 events/hour.
• Wegovy (semaglutide) is NOT FDA-approved for OSA — there is no completed positive Phase 3 OSA trial of semaglutide.
• You still need a sleep study (HSAT or in-lab PSG) to qualify. AHI ≥ 15 with BMI ≥ 30 is the indication gate^[8].
• CPAP remains first-line at diagnosis for most patients. Zepbound is an adjunct or alternative, not a replacement, and CPAP de-escalation requires a repeat sleep study.
• Build the care team early: sleep medicine for diagnosis and follow-up sleep studies, obesity medicine or primary care for the Zepbound prescription and titration.

Related research and tools

• SURMOUNT-OSA trial deep dive: what tirzepatide actually did in sleep apnea — the per-endpoint walk-through of the trial behind the FDA approval
• GLP-1 for fatty liver and MASH: the patient action plan — the parallel comorbidity-focused patient guide
• GLP-1 insurance coverage in 2026 — how Medicare Part D, Medicaid, and commercial insurance treat Zepbound and Wegovy
• Foundayo vs Wegovy vs Zepbound — how the three FDA-approved options differ on indication, dosing, and trial evidence
• Tirzepatide (Zepbound and Mounjaro) — full drug profile including the OSA indication
• What to eat on a GLP-1: the protein-first guide — the meal-pattern guidance during titration
• Zepbound and insomnia: what the evidence shows — the related sleep-quality side-effect picture during titration

Important disclaimer. This article is educational and does not constitute medical advice. Do not stop CPAP or change OSA treatment without sleep-medicine supervision. Untreated moderate-to-severe OSA is associated with cardiovascular risk that the patient typically cannot feel. The Zepbound-for-OSA indication is limited to adults with moderate-to-severe OSA (AHI ≥ 15) and obesity (BMI ≥ 30); it does not generalize to mild OSA, non-obese OSA, central or complex sleep apnea, or pediatric OSA. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28. Insurance coverage is plan-specific and changes frequently; verify with your prescriber and benefits administrator before assuming approval.

Last verified: 2026-05-28. Next review: every 6 months, or sooner if the FDA updates the Zepbound label or a semaglutide OSA trial reports.